SLS SELLAS Life Sciences Group, Inc. - Common Stock
Über SELLAS Life Sciences Group, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..
Mehr lesen
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigation their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SLS Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
SLS Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
SLS Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
- Starker Kauf 1 16,7%
- Kauf 4 66,7%
- Halten 1 16,7%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
2 Analysten · 2026-08-14Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 31. März 2026 | $-0.05 | $-0.04 | -0.01% |
| 31. Dezember 2025 | $-0.05 | $-0.07 | 0.02% |
| 30. September 2025 | $-0.06 | $-0.07 | 0.01% |
| 30. Juni 2025 | $-0.07 | $-0.08 | 0.01% |
| 31. März 2025 | $-0.07 | $-0.11 | 0.04% |
| 31. Dezember 2024 | $-0.08 | $-0.11 | 0.03% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
Bilanz 22
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
Cashflow 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
Liquidität & Solvenz 4
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
Effizienz 1
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
Wachstumsraten 1
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
Bewertung (TTM) 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
Gewinn- und Verlustrechnung 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
Bilanz 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
Cashflow 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
Rentabilität 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
Effizienz 1
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Bewertung (TTM) 9
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $1M | · | $1M | |
| Net Income TTM | $-31M | $-28M | · | $-26M | $-27M | $-30M | · | $-33M | $-35M | $-39M | · | $-36M | $-35M | $-43M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -64.2 | -16.9 | · | -5.4 | -5.9 | -2.1 | · | -1.6 | -1.2 | -0.8 | · | -1.1 | -1.0 | -0.6 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 40.5 | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.6% | -5.9% | · | -18.6% | -16.9% | -47.2% | · | -61.6% | -82.3% | -130.7% | · | -88.4% | -97.5% | -158.7% | · | -111.4% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | — | — | $0 | $1M | $8M |
| Betriebsgewinnmarge % | — | — | — | -4195.0% | -332.8% |
| Nettoergebnis | $-27M | $-31M | $-37M | $-41M | $-21M |
| Verwässerte EPS | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 231 Einreicher · $1.2B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 87 (+24 vs. Vorquartal) | 19 (+4 vs. Vorquartal) | 70 (+12 vs. Vorquartal) | 38 (+15 vs. Vorquartal) | +39.9M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| STATE STREET CORP | $191.829.196 | 12.996.558 | 15,97% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $121.417.310 | 8.226.105 | 10,11% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105.640.272 | 7.157.200 | 8,79% | Kaufoption |
| Anson Funds Management LP | $66.420.000 | 4.500.000 | 5,53% | Aktien |
| CITADEL ADVISORS LLC | $64.157.292 | 4.346.700 | 5,34% | Kaufoption |
| GEODE CAPITAL MANAGEMENT, LLC | $61.905.400 | 4.193.009 | 5,15% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61.832.592 | 4.189.200 | 5,15% | Verkaufsoption |
| CITADEL ADVISORS LLC | $33.333.984 | 2.258.400 | 2,77% | Verkaufsoption |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31.897.821 | 2.161.099 | 2,66% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30.266.812 | 2.050.597 | 2,52% | Aktien |
| JONES FINANCIAL COMPANIES LLLP | $28.553.511 | 2.304.561 | 2,38% | Aktien |
| VANGUARD GROUP INC | $27.868.421 | 7.392.154 | 2,32% | Aktien |
| Anson Funds Management LP | $27.245.484 | 1.845.900 | 2,27% | Verkaufsoption |
| PERCEPTIVE ADVISORS LLC | $22.140.000 | 1.500.000 | 1,84% | Verkaufsoption |
| VANGUARD FIDUCIARY TRUST CO | $19.707.050 | 1.335.166 | 1,64% | Aktien |
| Sio Capital Management, LLC | $18.165.132 | 1.230.700 | 1,51% | Verkaufsoption |
| BNP PARIBAS FINANCIAL MARKETS | $15.823.045 | 1.072.022 | 1,32% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $13.372.560 | 906.000 | 1,11% | Verkaufsoption |
| BARCLAYS PLC | $11.831.616 | 801.600 | 0,98% | Verkaufsoption |
| Anson Funds Management LP | $11.808.000 | 800.000 | 0,98% | Kaufoption |
| BNP PARIBAS FINANCIAL MARKETS | $11.734.200 | 7.950 | 0,98% | Verkaufsoption |
| JANE STREET GROUP, LLC | $11.058.192 | 749.200 | 0,92% | Kaufoption |
| MORGAN STANLEY | $9.922.380 | 672.248 | 0,83% | Aktien |
| BANK OF AMERICA CORP /DE/ | $9.150.359 | 619.943 | 0,76% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8.339.518 | 565.008 | 0,69% | Aktien |
| JANE STREET GROUP, LLC | $7.462.700 | 505.603 | 0,62% | Aktien |
| Balyasny Asset Management L.P. | $7.380.000 | 500.000 | 0,61% | Verkaufsoption |
| LMR Partners LLP | $6.642.000 | 450.000 | 0,55% | Verkaufsoption |
| NOMURA HOLDINGS INC | $6.273.000 | 425.000 | 0,52% | Kaufoption |
| DIADEMA PARTNERS LP | $5.904.000 | 400.000 | 0,49% | Kaufoption |
| Swiss National Bank | $5.319.504 | 360.400 | 0,44% | Aktien |
| XTX Topco Ltd | $5.300.168 | 359.090 | 0,44% | Aktien |
| Ikarian Capital, LLC | $5.235.372 | 354.700 | 0,44% | Verkaufsoption |
| CITIGROUP INC | $4.659.717 | 315.699 | 0,39% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $4.580.973 | 310.364 | 0,38% | Aktien |
| DAGCO, INC. | $4.351.740 | 1.028.780 | 0,36% | Aktien |
| Everhart Financial Group, Inc. | $4.251.146 | 288.018 | 0,35% | Aktien |
| Rafferty Asset Management, LLC | $3.540.806 | 239.892 | 0,29% | Aktien |
| RHUMBLINE ADVISERS | $3.400.726 | 230.402 | 0,28% | Aktien |
| Walleye Capital LLC | $3.377.088 | 228.800 | 0,28% | Verkaufsoption |
| GOLDMAN SACHS GROUP INC | $3.125.991 | 211.788 | 0,26% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $3.087.792 | 209.200 | 0,26% | Verkaufsoption |
| WELLINGTON MANAGEMENT GROUP LLP | $2.992.738 | 202.760 | 0,25% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.982.996 | 202.100 | 0,25% | Verkaufsoption |
| Jefferies Financial Group Inc. | $2.958.775 | 200.459 | 0,25% | Aktien |
| Jefferies Financial Group Inc. | $2.953.476 | 200.100 | 0,25% | Verkaufsoption |
| Mariner, LLC | $2.925.609 | 198.212 | 0,24% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $2.895.912 | 196.200 | 0,24% | Kaufoption |
| Bank of New York Mellon Corp | $2.801.212 | 189.784 | 0,23% | Aktien |
| ALPS ADVISORS INC | $2.776.459 | 188.107 | 0,23% | Aktien |
| JANE STREET GROUP, LLC | $2.405.880 | 163.000 | 0,20% | Verkaufsoption |
| LPL Financial LLC | $2.297.586 | 155.663 | 0,19% | Aktien |
| SIMPLEX TRADING, LLC | $2.274.501 | 154.099 | 0,19% | Aktien |
| BlackRock, Inc. | $2.222.708 | 150.590 | 0,19% | Aktien |
| WELLS FARGO & COMPANY/MN | $2.208.775 | 149.646 | 0,18% | Aktien |
| Vontobel Holding Ltd. | $2.166.207 | 146.762 | 0,18% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $2.069.352 | 140.200 | 0,17% | Kaufoption |
| Vanguard Global Advisers, LLC | $1.918.874 | 130.005 | 0,16% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.859.598 | 125.989 | 0,15% | Aktien |
| Caption Management, LLC | $1.845.000 | 125.000 | 0,15% | Verkaufsoption |
| PROFUND ADVISORS LLC | $1.780.159 | 120.607 | 0,15% | Aktien |
| MetLife Investment Management, LLC | $1.624.810 | 110.082 | 0,14% | Aktien |
| Daiwa Securities Group Inc. | $1.589.652 | 107.700 | 0,13% | Verkaufsoption |
| Daiwa Securities Group Inc. | $1.512.900 | 102.500 | 0,13% | Aktien |
| DIADEMA PARTNERS LP | $1.476.000 | 100.000 | 0,12% | Verkaufsoption |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $1.467.144 | 99.400 | 0,12% | Aktien |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.405.300 | 95.210 | 0,12% | Aktien |
| Harvest Investment Services, LLC | $1.394.554 | 94.482 | 0,12% | Aktien |
| ORBIMED ADVISORS LLC | $1.365.300 | 92.500 | 0,11% | Verkaufsoption |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $1.229.582 | 83.305 | 0,10% | Aktien |
| Invesco Ltd. | $1.104.816 | 74.852 | 0,09% | Aktien |
| Gotham Asset Management, LLC | $1.097.317 | 74.344 | 0,09% | Aktien |
| FULCRUM WEALTH ADVISORS, LLC | $1.081.214 | 73.253 | 0,09% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $998.534 | 236.060 | 0,08% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $978.588 | 66.300 | 0,08% | Aktien |
| Verition Fund Management LLC | $916.596 | 62.100 | 0,08% | Verkaufsoption |
| OSAIC HOLDINGS, INC. | $889.776 | 60.284 | 0,07% | Aktien |
| FIFTH THIRD BANCORP | $888.404 | 60.190 | 0,07% | Aktien |
| State of New Jersey Common Pension Fund D | $857.069 | 58.067 | 0,07% | Aktien |
| Verition Fund Management LLC | $832.464 | 56.400 | 0,07% | Kaufoption |
| Police & Firemen's Retirement System of New Jersey | $821.630 | 55.666 | 0,07% | Aktien |
| ARIZONA STATE RETIREMENT SYSTEM | $731.388 | 49.552 | 0,06% | Aktien |
| Caption Management, LLC | $728.745 | 49.373 | 0,06% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $722.310 | 48.937 | 0,06% | Aktien |
| Russell Investments Group, Ltd. | $704.494 | 47.730 | 0,06% | Aktien |
| SIG BROKERAGE, LP | $689.292 | 46.700 | 0,06% | Kaufoption |
| Vanguard Investments Australia, Ltd. | $684.643 | 46.385 | 0,06% | Aktien |
| COMMONWEALTH EQUITY SERVICES, LLC | $665.481 | 45.087 | 0,06% | Aktien |
| INSTRUMENTAL WEALTH, LLC | $662.931 | 44.914 | 0,06% | Aktien |
| Persistent Asset Partners Ltd | $655.647 | 758 | 0,05% | Kaufoption |
| Virtus Investment Advisers, LLC | $616.791 | 41.788 | 0,05% | Aktien |
| Accurate Wealth Management, LLC | $614.707 | 47.462 | 0,05% | Aktien |
| AXXCESS WEALTH MANAGEMENT, LLC | $610.665 | 41.373 | 0,05% | Aktien |
| KLP KAPITALFORVALTNING AS | $600.732 | 40.700 | 0,05% | Aktien |
| SJS Investment Consulting Inc. | $590.400 | 40.000 | 0,05% | Aktien |
| Wealthfront Advisers LLC | $587.773 | 39.822 | 0,05% | Aktien |
| Quantinno Capital Management LP | $546.651 | 37.036 | 0,05% | Aktien |
| Visionary Horizons, LLC | $531.360 | 36.000 | 0,04% | Aktien |
| Kestra Advisory Services, LLC | $516.305 | 34.980 | 0,04% | Aktien |
| NORTHSTAR ASSET MANAGEMENT Co | $509.400 | 45.000 | 0,04% | Aktien |
Unternehmensinsider 42 Insider · 17 Führungskräfte · 9 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 16. Juni 2026 A | 1.759.183 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 15. März 2011 A | 92.994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 7. Januar 2026 A | 554.327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 20. April 2018 A | — | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 13. April 2011 A | 379.294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 15. Januar 2009 A | — | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 7. Januar 2026 A | 557.805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 22. Januar 2024 A | 40.918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 22. Januar 2024 A | 117.225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 14. März 2019 A | — | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 13. März 2018 A | — | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 15. März 2011 A | 14.065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 15. März 2011 A | 41.083 | 0 | 0 | $0 |
| Anastasia Khvorova | Chief Science Officer | 15. März 2011 A | 60.559 | 0 | 0 | $0 |
| Pamela Pavco | VP of Pharmaceutical Devlpmt | 15. März 2011 A | 44.940 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 15. April 2010 A | 5.750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 31. März 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | Direktor | 7. Januar 2026 A | 154.400 | 1 | 0 | $100.806 |
| John Varian | Direktor | 7. Januar 2026 A | 72.900 | 0 | 0 | $0 |
| Jane Wasman | Direktor | 7. Januar 2026 A | 92.900 | 0 | 0 | $0 |
| David A Scheinberg | Direktor | 7. Januar 2026 A | 73.082 | 0 | 0 | $0 |
| Robert L Van Nostrand | Direktor | 7. Januar 2026 A | 82.900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | Direktor | 14. März 2019 A | — | 0 | 0 | $0 |
| Fabio Lopez | Direktor | 12. Juni 2018 A | — | 0 | 0 | $0 |
| Irving M. Einhorn | — | 10. Oktober 2017 A | 34.690 | 0 | 0 | $0 |
| William Ashton | — | 10. Oktober 2017 A | 38.154 | 0 | 0 | $0 |
| Richard Chin | — | 10. Oktober 2017 A | 31.339 | 0 | 0 | $0 |
| Rudolph Nisi | — | 10. Oktober 2017 A | 42.918 | 0 | 0 | $0 |
| Sanford Hillsberg | — | 10. Oktober 2017 A | 56.950 | 0 | 0 | $0 |
| Mary Ann Gray | — | 10. Oktober 2017 A | 39.167 | 0 | 0 | $0 |
| Stephen S Galliker | — | 10. Oktober 2017 A | 36.039 | 0 | 0 | $0 |
| Thomas J Knapp | — | 6. Februar 2017 A | — | 0 | 0 | $0 |
| Bijan Nejadnik | — | 17. Januar 2017 A | — | 0 | 0 | $0 |
| Ryan Dunlap | — | 1. Juni 2016 M | 18.702 | 0 | 0 | $0 |
| Mark W. Schwartz | — | 18. Dezember 2015 A | 415.972 | 0 | 0 | $0 |
| Steven A Kriegsman | — | 19. Juni 2015 A | 5.000 | 0 | 0 | $0 |
| Margaret Kivinski | — | 16. Januar 2015 A | — | 0 | 0 | $0 |
| Brian L Hamilton | — | 30. Juni 2014 J | 2.461 | 0 | 0 | $0 |
| Mark J Ahn | — | 30. Juni 2014 A | 116.225 | 0 | 0 | $0 |
| Rosemary Mazanet | — | 29. Januar 2013 A | — | 0 | 0 | $0 |
| CYTRX CORP | — | 29. Dezember 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | — | 15. Januar 2009 A | — | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 Einreichungen | 10. Oktober 2018 | — | Erste Einreichung | — | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 8. Januar 2018 | — | Erste Einreichung | M&A / Verkauf | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 29 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,77% | 288.499 SH | 8. August 2026 | Täglich |
| IWC · iShares Trust | 0,50% | 640.415 SH | 8. August 2026 | Täglich |
| LABU · Direxion Shares ETF Trust | 0,26% | 268.465 NS | 30. April 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,23% | 316.525 SH | 8. August 2026 | Täglich |
| ICOP · iShares Trust | 0,22% | 126.361 SH | 8. August 2026 | Täglich |
| CANC · Tema ETF Trust | 0,22% | 40.702 NS | 31. Mai 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,16% | 202.339 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,14% | 1.712.069 SH | 8. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,08% | 1.086.285 SH | 8. August 2026 | Täglich |
| IWM · iShares Trust | 0,07% | 4.828.431 SH | 8. August 2026 | Täglich |
| ISCG · iShares Trust | 0,07% | 57.511 SH | 8. August 2026 | Täglich |
| GSSC · Goldman Sachs ETF Trust | 0,05% | 51.293 NS | 31. Mai 2026 | N-PORT |
| PICK · iShares, Inc. | 0,04% | 122.564 SH | 8. August 2026 | Täglich |
| ITWO · ProShares Trust | 0,04% | 8.088 NS | 31. Mai 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,04% | 540.244 SH | 8. August 2026 | Täglich |
| ISCF · iShares Trust | 0,04% | 30.200 SH | 8. August 2026 | Täglich |
| ISCB · iShares Trust | 0,03% | 8.283 SH | 8. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.134.285 SH | 8. August 2026 | Täglich |
| WSML · iShares Trust | 0,03% | 16.889 SH | 8. August 2026 | Täglich |
| RSSL · Global X Funds | 0,03% | 74.459 NS | 30. April 2026 | N-PORT |
| UWM · ProShares Trust | 0,02% | 6.326 NS | 31. Mai 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 6.397 NS | 31. Mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 161 NS | 31. Mai 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 64.480 NS | 31. Mai 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 3.554 NS | 31. Mai 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 273.812 SH | 8. August 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 43.929 SH | 8. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.908.560 SH | 8. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 15.706 SH | 8. August 2026 | Täglich |